Annexon, INC

Annexon, Inc. announced second quarter 2026 financial results, business updates including expansion of its Vonaprument Phase 3 program for geographic atrophy, and a $200 million credit facility.

Annexon's FORWARD study shows rapid, positive clinical responses in all Guillain-Barré Syndrome patients treated with tanruprubart within one week, reinforcing its potential as a first-in-class targeted therapy.

Annexon, Inc. has entered into a strategic credit facility agreement with Oxford Finance LLC for up to $200 million to support its biopharmaceutical programs.

Annexon, Inc. announced the results of its 2026 Annual Meeting, with shareholders electing two Class III directors, ratifying KPMG as auditors, approving executive compensation, and increasing authorized common stock.

Annexon reported higher FY25 R&D spend, an EU MAA filing for GBS, $238.3M in cash with runway into H2 2027, and expects pivotal GA data in Q4 2026.

Annexon, Inc. updated its corporate presentation, highlighting significant progress in its late-stage neuroinflammatory disease pipeline, including Vonaprument for dry AMD with GA and Tanruprubart for Guillain-Barré Syndrome.

Annexon, Inc. reported a significant increase in net loss and R&D expenses for Q3 2025, while advancing its lead clinical programs and extending its cash runway into late Q1 2027.

Annexon, Inc. reported a significant increase in net losses and R&D expenses in Q2 2025, driven by advanced clinical trials, while projecting its cash runway into Q4 2026 and signaling a need for substantial future financing.

Annexon, a biopharmaceutical company, announced its Q1 2025 financial results, showcasing increased R&D spending and progress in its clinical programs for Guillain-Barr Syndrome (GBS), Geographic Atrophy (GA), and autoimmune indications.

Annexon Inc. reports a net loss of $34.8 million for the third quarter of 2024, while highlighting progress in its clinical programs and financial position.

Annexon, a clinical-stage biopharmaceutical company, announced its second quarter 2024 results, highlighting progress in its key clinical programs and financial position.

Annexon Inc. released its 10-Q filing for the quarter ended March 31, 2024, detailing financial results and providing updates on its clinical programs.

Annexon posted a $206.7M 2025 net loss, filed an EMA MAA for GBS, guided to a 2026 U.S. BLA and GA Phase 3 topline in 4Q26, and added a new $150M ATM financing facility.

Annexon's 10-K filing highlights progress in its GBS program with a planned BLA submission in early 2025 and the advancement of its GA trial, while reporting a net loss of $138.2 million for 2024.

Annexon Inc.'s 10-K filing details the company's financial status and progress in developing treatments for complement-mediated diseases, including Guillain-Barr Syndrome (GBS) and Geographic Atrophy (GA).

Mark S. Blumenkranz, a Director of Annexon, Inc., received 175,000 shares of common stock on August 10, 2026.

Annexon, Inc. director Muneer A. Satter acquired 65,000 stock options with an exercise price of $4.70, vesting in June 2026.

Director William A. Jones Jr. acquired 65,000 stock options in Annexon, Inc. on June 11, 2026.

Bettina M. Cockroft, a Director at Annexon, Inc., was granted 65,000 stock options with an exercise price of $4.70, vesting on June 11, 2026.

Annexon, Inc. director Jung Choi acquired 65,000 stock options with an exercise price of $4.70, vesting under specific service conditions.

Annexon, Inc. director William H. Carson acquired 65,000 stock options with an exercise price of $4.70, vesting under specific service conditions.

Annexon, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to be held virtually, and is seeking approval to increase its authorized common stock.

Annexon, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Annexon, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors, ratify the selection of KPMG LLP as the independent accounting firm, and approve executive compensation.

Annexon, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Annexon, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 5, 2024, to be held virtually.

Muneer A. Satter, through Alerce Medical, increased his beneficial ownership in Annexon, Inc. to 7.2% by purchasing an additional 2.3 million shares for approximately $8.7 million.

State Street Corporation has disclosed beneficial ownership of 6% of Annvon Inc.'s common stock as of June 30, 2026.

Redmile Group, LLC, along with Jeremy C. Green and RedCo II Offshore SPV LLC, has reported beneficial ownership of 9.9% of Annexon, Inc.'s common stock as of July 8, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 11.9% of Annexon Inc.'s common stock as of June 30, 2026.

Biotechnology Value Fund and its affiliates have disclosed a 5.4% beneficial ownership stake in Annexon, Inc. following the exercise of pre-funded warrants.

The Vanguard Group has amended its Schedule 13G for Annexon Inc., reporting 0% beneficial ownership following an internal realignment.

FMR LLC and Abigail P. Johnson have disclosed a 7.1% beneficial ownership stake in Annexon Inc. common stock as of December 31, 2025.